Overview

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

This study is a prospective trial of Alimta (pemetrexed) versus IRESSA (gefitinib) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer (NSCLC) patients in a 2nd line setting.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese Society of Lung Cancer

Treatments:

Gefitinib
Pemetrexed